The lukewarm day-one reception on Wall Street last week for Myriad Genetics Inc.'s spin-off of Myriad Pharmaceuticals Inc. foretells neither the success of the new firm nor of similar models tried by other companies, but it does sharpen the points on some of the questions raised by those earlier attempts - and shows what a difference timing can make. Read More
